STAT

MAY 12, 2024

Slayman, who lived in Weymouth and   worked as a manager with the state Department of Transportation, developed kidney failure as a result of diabetes and hypertension and had been on dialysis for years, Dr. Winfred Williams, associate chief of the renal division at Mass.

Hospitals 345

Hospitals Diabetes 345

BioPharma Dive

JUNE 29, 2023

Sigilon Therapeutics, a biotech that’s been collaborating with Lilly since 2018, has agreed to be bought for up to $310 million in the pharma’s second announced buyout this month.

Diabetes 101

Diabetes 101

PharmaShots

JUNE 13, 2023

Eisai's and Merck Announces EU's Marketing Approval of Lenvima (lenvatinib mesylate) for Hepatocellular Carcinoma Published: 23 Aug,2018 | Tags: Eisai, Merck, Approval, Lenvima, HCC, 2. Pfizer to co-promote Exact Sciences Cologuard Published: 22 Aug,2018 | Tags: Exact, Pfizer, Agreement, Promote, Cologuard 7.

Biosimilars 52

Biosimilars Labelling Diabetes 52

pharmaphorum

AUGUST 11, 2020

In our latest UK Leaders article Pinder Sahota, UK general manager at Novo Nordisk, tells us how he hopes to bring the NHS and pharma together to improve outcomes in diabetes and other long-term conditions. Collaborating to prevent diabetes. We’ve got two such projects in the UK, in Leicester and Manchester,” says Sahota. “We

Diabetes 111

Diabetes Packaging Communication 111

European Pharmaceutical Review

AUGUST 14, 2023

Eli Lilly and Company has completed acquisition of two biopharmaceutical companies – Versanis Bio and Sigilon Therapeutics – and their lead assets focused on obesity and diabetes. Sigilon Therapeutics deal for diabetes cell therapy In a separate announcement, Lilly confirmed it has acquired Sigilon Therapeutics , Inc.

Diabetes 98

Diabetes 98

pharmaphorum

JANUARY 31, 2022

Glooko has made a name for itself in digital health circles with its data management tools for diabetes patients, and has now added artificial intelligence capabilities with an agreement to acquire xbird. The post Glooko adds AI to its digital diabetes tools with xbird takeover appeared first on. billion deal in 2020.

Diabetes 52

Diabetes 52

pharmaphorum

JULY 14, 2021

For a diabetes specialist like Lilly that is an enticing prospect, but Protomer is also planning applications of its platform in other therapeutic areas, for example by developing peptide or proteins that could be activated in the body by small molecule drugs.

Diabetes 98

Diabetes 98

ALiEM - Pharm Pearls

DECEMBER 8, 2023

Additionally, cardiovascular co-morbidities, such as obesity, hypertension, and diabetes, can increase the risk. 2018 Apr;22(2):353-361. Epub 2018 Jan 27. The major risk factor that predisposes patients to the development of abdominal wall hernias is a decrease in the strength of the abdominal wall musculature. PMID: 32310432.

Diabetes 152

Diabetes 152

pharmaphorum

JULY 12, 2022

In diabetes, for example, consistent engagement in self-management, including medication adherence, is associated with better blood glucose control, fewer complications, improved quality of life, and reductions in diabetes-related death risk. In diabetes, for example, 25% of patients experience depression and 40% experience anxiety.

Diabetes 111

Diabetes Hospitals 111

Express Pharma

AUGUST 23, 2024

Skin and soft tissue infections are the most common type of infections constituting, around 29-32 per cent of all infections in 2018-2019 in India. The treatment of ABSSSI is further complicated by associated comorbidities such as diabetes, obesity, renal and hepatic dysfunction in these patients. The incidence of invasive S.

Diabetes 105

Diabetes 105

European Pharmaceutical Review

JANUARY 17, 2023

Ximluci ® has been approved in the UK for treating wet age-related macular degeneration (wet AMD), diabetic macular oedema (DME), diabetic retinopathy (PDR), retinal vein occlusion (RVO) and visual impairment due to choroidal neovascularization (CNV) in adults. A biosimilar for biologic ophthalmic treatments. “We

Biosimilars 104

Biosimilars Diabetes 104

ALiEM - Pharm Pearls

DECEMBER 4, 2023

2018 May 9;13:158-163. doi: 10.1515/med-2018-0025. Yang TY, Wang TY, Chen M, Sun FJ, Chiu AW, Chen YH. Penile Calciphylaxis in a Patient with End-stage Renal Disease: A Case Report and Review of the Literature. Open Med (Wars). PMID: 29756051; PMCID: PMC5941707.

Hospitals 152

Hospitals Medical Schools Diabetes 152

ALiEM - Pharm Pearls

SEPTEMBER 25, 2023

66 year-old-male with a history of type 2 diabetes and hypertension presented as a transfer for rapid progression of lower extremity pain, swelling, and blue-purple discoloration of the entire limb with concern for a possible necrotizing infection. 2018 Sep 25;11(3):355-357. He had no known thromboembolic risk factors. Ann Vasc Dis.

Medical Schools 152

Medical Schools Diabetes 152

pharmaphorum

JANUARY 17, 2022

Founded in 2018 as a spin-off of the University of Zurich and Harvard University, EraCal is already using this technology to develop a novel anti-obesity drug, named Era-379. Securing FDA approval was a huge development for the obesity space, marking the first approval for a weight management drug to be granted by the regulator since 2014.

Diabetes 123

Diabetes Pharmaceutical Companies Pharmaceutical Companies 123

ALiEM - Pharm Pearls

SEPTEMBER 9, 2024

A 61-year-old female with a past medical history of hypertension, hyperlipidemia, type 2 diabetes, and normal pressure hydrocephalus s/p VP shunt (last revision nine months ago) presented to the Emergency Department (ED) for evaluation after noticing a “string” coming out of her anus today. Ventriculoperitoneal shunt complications: A review.

Diabetes 152

Diabetes Hospitals 152

Express Pharma

APRIL 17, 2024

billion in total partnership deal value from 2018 to 2024YTD, where 2024YTD is already the top year for MASH partnerships by deal value. Note: Data in the chart includes all announced and completed partnership deals globally from 2018 to 2024YTD.

Drug Development 95

Drug Development Diabetes 95

European Pharmaceutical Review

JUNE 28, 2022

“Empagliflozin is an oral, once daily, highly selective sodium-glucose cotransporter 2 or SGLT2 inhibitor… It was originally developed for type 2 diabetes because it improves glycaemic control,” explained Dr Clark. of type 2 diabetes patients overall and was the cause of death for 10 percent of type 2 diabetes patients.

Diabetes 98

Diabetes 98

Express Pharma

APRIL 24, 2023

Adults above 50 years of age and those suffering from chronic conditions such as diabetes, heart disease and kidney diseases are at an increased risk of developing shingles because of weakened immunity. The European Commission gave Shingrix approval for the prevention of shingles in adults 50 years of age or older in 2018.

Vaccines 97

Vaccines Diabetes Immunity Immunization 97

The Thyroid Pharmacist

SEPTEMBER 2, 2022

A review paper published in 2010 that discussed the relationship between thyroid dysfunction and metabolic disorders, highlighted the fact that patients with diabetes were up to three times more likely to develop a thyroid disorder. (7). Hypoglycemia is an early risk factor for developing diabetes. Type 2 Diabetes.

Diabetes 98

Diabetes Health and Personal Care Stores Immunity Immunization 98

pharmaphorum

MARCH 18, 2021

The toolkit – or the AMAZE Disease Management Platform to give it its full name – is designed to bring patients with conditions like asthma, chronic obstructive pulmonary disease (COPD), heart failure, chronic kidney disease, and diabetes close to healthcare providers.

Diabetes 90

Diabetes Communication Hospitals 90

Pharma in Brief

MARCH 1, 2024

The legislation includes a commitment to first launch diabetes medication and contraceptives coverage for Canadians through a universal, single-payer system, contingent on provincial and territorial agreement. Bill C-64 was introduced and had its first reading on February 29, 2024 in the House of Commons.

Diabetes 52

Diabetes 52

pharmaphorum

JANUARY 6, 2021

million – including $175 million upfront and an equity investment of $50 million – to find multiple RNA interference (RNAi) candidates for diseases like non-alcoholic steatohepatitis (NASH) and type 2 diabetes. Danish drugmaker Novo Nordisk signed a deal with the US biotech in 2019 valued at up to $675.5

Diabetes 66

Diabetes Drug Development 66

pharmaphorum

DECEMBER 1, 2022

In another win for Bayer, the Scottish Medicines Consortium (SMC) has accepted the company’s chronic kidney disease (CKD) drug, Kerendia (finerenone), for the treatment of adults with CKD associated with type 2 diabetes (T2D) in NHS Scotland.

Diabetes 59

Diabetes Hospitals 59

pharmaphorum

OCTOBER 13, 2020

Mortazavi, who stepped down as CEO of Silence Therapeutics in 2018, was appointed executive chairman in February in a management restructure that saw CEO Ray Barlow and CFO Steve Medlicott step down. That restructure was accompanied by a £1.6 million fundraiser to keep the company running and was followed by another £11.6m

Diabetes 100

Diabetes 100

pharmaphorum

NOVEMBER 26, 2021

This year, China has started to include insulin in its centralised procurement programme, first introduced in 2018, forcing producers to enter into a tender process to get their products included in a national formulary. billion) of diabetes drugs there in the first nine months of this year, 75% of which was insulin.

Diabetes 59

Diabetes Hospitals 59

The Thyroid Pharmacist

OCTOBER 7, 2022

I knew he was right — sugar can contribute to a yeast overgrowth, lowered immunity, blood sugar issues, weight gain, diabetes, and a whole host of health problems (1-3) — but I was a sugar addict, and it was devastating to think that I would have to let go of this old friend and not have any sweetness in my life.

Diabetes 98

Diabetes Immunity Immunization Labelling 98

RX Note

NOVEMBER 1, 2023

Introduction Controlling glycemia is an integral component of diabetes mellitus management. Hence, it is very useful in monitoring of patient's actual blood glucose control (apart from to diagnose diabetes mellitus ) and the result is independent of fasting status. It provides an instantaneous glucose level result.

Diabetes 52

Diabetes Community Pharmacies 52

pharmaphorum

DECEMBER 3, 2020

Janssen established its eye disease portfolio in 2018 and is developing expertise and assets across a range of rare and common eye diseases, including achromatopsia and X-linked retinitis pigmentosa, age-related macular degeneration, diabetic retinopathy, and diabetic macular oedema.

Diabetes 59

Diabetes 59

pharmaphorum

MAY 12, 2021

Lilly is paying $25 million upfront to explore the use of MiNA’s platform to develop saRNA drugs for up to five targets across the drugmaker’s main therapeutic categories, which include cancer, diabetes, immunology, neurodegenerative diseases and pain.

Diabetes 76

Diabetes 76

pharmaphorum

OCTOBER 28, 2020

Therapeutic areas range from diabetes to ulcerative colitis and smoking cessation. billion for the first nine months of the year, already well ahead of the previous annual record set in 2018 of $8.2 This brings the fundraising total to $9.4

Diabetes 75

Diabetes 75

Big Molecule Watch

JULY 9, 2024

The FDA approved AHZANTIVE for the treatment of patients with Age-Related Neovascular (wet) Macular Degeneration (nAMD) and other serious retinal diseases such as Diabetic Macular Edema (DME), Diabetic Retinopathy (DR) and Macular Edema following Retinal Vein Occlusion (RVO).

Biosimilars 49

Biosimilars Diabetes 49

PharmD Live

MAY 13, 2024

However, aging also brings about physiological and pathological changes that increase the risk of developing multiple chronic diseases, such as cardiovascular disease, stroke, and diabetes. “Health Literacy and Its Impact on Medication Adherence,” Pharmacy Journal , 2018). Reference: Lee, W. & & Kim, T.

Long-Term Care Facilities 105

Long-Term Care Facilities Diabetes Nursing Homes Prescription Filling 105

pharmaphorum

AUGUST 24, 2021

The latest deal allows Vertex to tap into Arbor’s technology platform to develop cell therapies for diseases like type 1 diabetes and blood disorders sickle cell disease (SCD) and beta thalassaemia.

Diabetes 52

Diabetes 52

Pharmaceutical Technology

MAY 19, 2023

It received approval from the US Food and Drug Administration in October 2018. Yutiq is indicated to treat chronic, non-infectious uveitis that affects the posterior segment of the eye.

Diabetes 52

Diabetes Drug Development 52

pharmaphorum

JANUARY 6, 2023

Prior to RxWare, Knobel was head of mobile at AgaMatrix Diabetes. When any organisation looks to slash its budget, the old adage about acquiring new customers costing five times as much as retaining existing customers becomes an alluring data point. in 1979 to 2.8%in About the author.

Diabetes 105

Diabetes Pharmaceutical Companies Pharmaceutical Companies 105

RX Note

JANUARY 21, 2023

Regardless, this post is solely created as a collection of recommended reference.

Compounding 40

Compounding Community Pharmacies Clinical Pharmacology Dosage 40

PharmD Live

APRIL 20, 2022

Obesity rates are at an all-time high at 42.4%, according to the latest CDC records from 2017 to 2018. 1 Obesity increases the risk for many health problems, such as type 2 diabetes, high blood pressure, heart disease, stroke, joint disorders, liver disease, gallstones, some types of cancer, and sleep apnea among other conditions.

Diabetes 52

Diabetes Hospitals 52